Naveen Babbar

SVP of Translation Medicine at Prelude Therapeutics

Naveen Babbar is Senior Vice President, Translation Medicine. Before joining Prelude, Naveen was Vice President of Global Precision Medicine at Novartis Pharmaceuticals. Naveen’s experience covers a wide span of solid tumor oncology drug and device development including translational studies across early and late-stage development, diagnostic assay development, global registrations, and commercial launches. Naveen has contributed to successful NDA submissions for Zykadia® (ALK inhibitor), Kisqali® (CDK4/6 inhibitor), Piqray® (PIK3CA inhibitor), and Tabrecta® (cMET inhibitor), and their associated companion diagnostic assays globally. Naveen received his M.Sc. in Biotechnology from Delhi, India, Ph.D. in Biochemistry and Molecular Biology from the University of Arizona, and completed his postdoctoral fellowship from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

Location

Cambridge, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Prelude Therapeutics

3 followers

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.


Industries

Employees

51-200

Links